Revvity announced that it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. The acquisition is expected to expand the Revvity Signals platform by enhancing its ability to bridge analytical data with actionable scientific insights. The transaction is anticipated to close in late Q4 2025.
ACD/Labs brings long-established expertise in analytical and process chemistry within pharmaceutical and chemical research workflows. Its solutions help scientists identify and characterize molecules, monitor quality and purity, and establish reliable production processes. The company’s platforms include the Spectrus Platform for advanced spectral analysis, the Percepta Platform for AI-driven molecular property and ADMET prediction, as well as specialized capabilities for high-throughput experimentation, pharmaceutical chemistry decision support, and enterprise analytical data management.
The combined capabilities of Revvity Signals and ACD/Labs are intended to support a seamless scientific workflow that connects discovery, development, scale-up, and manufacturing. The integrated offering is positioned to give researchers and enterprise users greater ability to manage, interpret, and act on complex data with improved speed and scientific consistency. This acquisition represents a continued expansion of Revvity’s presence in research informatics and development and manufacturing solutions.
KEY QUOTES
“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution. This acquisition adds meaningful value to our portfolio and reinforces the importance of analytical sciences as a driver of innovation across disciplines.”
Kevin Willoe, President of Revvity Signals Software
“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence. Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software. Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”
Daria Thorp, President and CEO of ACD/Labs
